Found 381 clinical trials
COG-PSYCHO : Social Cognition and Psychotic Characteristics: Genetic and Phenomic Approach
Bipolar disorder (BD), schizophrenia and depression can feature cognitive impairment, especially in social cognition (SC). According to previous studies, some genes from the oxytocin and
- 18 views
- 24 Jun, 2021
- 1 location
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
- 1341 views
- 28 Feb, 2022
- 1 location
Vitamin D in Pregnancy
Danish pregnant women are recommended ad daily vitamin D supplement of 10 g. Despite the fact that 9 out of 10 women take vitamin D supplements, more than 40% of pregnant women are vitamin D deficient, putting them at an increased risk of pregnancy complications like fetal growth restriction and …
- 0 views
- 06 May, 2021
- 2 locations
Peer and Text Message Support to Reduce Readmission Rates for Patients Discharged From Acute Psychiatric Care
Avoidable hospital readmissions are a pressing problem for our healthcare system. They lead to substantial human suffering and higher financial costs. Most discharged psychiatric inpatients in Alberta are offered follow-up appointments with Alberta Health Services (AHS) Addiction and Mental Health (AMH) community providers. Patients often wait 28-38 weeks for their …
- 0 views
- 20 Apr, 2022
- 5 locations
Health-Enhancing Adapted Physical Activity Program at "Mon Stade" (SESAME)
Introduction: Regular practice of exercise or physical activity (PA) is a recognized intervention as a determinant of good health acquisition, maintenance, or recovery for a large number of chronic pathologies. Nevertheless, few studies have evaluated adherence to an initial health-adapted PA (APA) program, and persistence of active behavior over the …
- 0 views
- 27 Apr, 2022
- 1 location
Inflammatory Response In Schizophrenia (IRIS)
Schizophrenia affects a significant proportion of the population and current levels of understanding of the illness is inadequate to treat it effectively. Converging lines of evidence suggest
- 0 views
- 21 Apr, 2022
- 1 location
Adjunctive Vortioxetine in Schizophrenia (AVIS)
with a research diagnosis of schizophrenia determined with the Structured Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness duration (i.e., </=5 years and >5
- 70 views
- 25 Apr, 2022
- 3 locations
Schizophrenia Treatment With Photoneuromodulation
Abstract: Randomized clinical trial that aims to see the efficacy of photoneuromodulation for the treatment of negative symptoms of schizophrenia in patients refractory to transcranial direct
- 0 views
- 05 May, 2022
- 1 location
Siltuximab in Schizophrenia
schizophrenia. Siltuximab (structural formula C6450H9932N1688O2016S50) is a recombinant chimeric (human-murine) anti-human interleukin-6 (IL-6) monoclonal antibody. Siltuximab is formulated as a concentrate for
- 93 views
- 23 Feb, 2022
- 1 location
Tocilizumab in Schizophrenia
schizophrenia. Tocilizumab (structural formula C6428H9976N1720O2018S42) is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin G1 (IgG1) subclass
- 290 views
- 23 Feb, 2022
- 1 location